Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Apr 1;556(Pt 1):221-34.
doi: 10.1113/jphysiol.2003.059659. Epub 2004 Jan 30.

Central CRF, urocortins and stress increase colonic transit via CRF1 receptors while activation of CRF2 receptors delays gastric transit in mice

Affiliations

Central CRF, urocortins and stress increase colonic transit via CRF1 receptors while activation of CRF2 receptors delays gastric transit in mice

Vicente Martínez et al. J Physiol. .

Erratum in

  • J Physiol. 2004 May 1;556(Pt 3):1013

Abstract

Recently characterized selective agonists and developed antagonists for the corticotropin releasing factor (CRF) receptors are new tools to investigate stress-related functional changes. The influence of mammalian CRF and related peptides injected intracerebroventricularly (i.c.v.) on gastric and colonic motility, and the CRF receptor subtypes involved and their role in colonic response to stress were studied in conscious mice. The CRF(1)/CRF(2) agonists rat urocortin 1 (rUcn 1) and rat/human CRF (r/h CRF), the preferential CRF(1) agonist ovine CRF (oCRF), and the CRF(2) agonist mouse (m) Ucn 2, injected i.c.v. inhibited gastric emptying and stimulated distal colonic motor function (bead transit and defecation) while oCRF(9-33)OH (devoid of CRF receptor affinity) showed neither effects. mUcn 2 injected peripherally had no colonic effect. The selective CRF(2) antagonist astressin(2)-B (i.c.v.), at a 20 : 1 antagonist: agonist ratio, blocked i.c.v. r/hCRF and rUcn 1 induced inhibition of gastric transit and reduced that of mUcn 2, while the CRF(1) antagonist NBI-35965 had no effect. By contrast, the colonic motor stimulation induced by i.c.v. r/hCRF and rUcn 1 and 1h restraint stress were antagonized only by NBI-35965 while stimulation induced by mUcn 2 was equally blocked by both antagonists. None of the CRF antagonists injected i.c.v. alone influenced gut transit. These data establish in mice that brain CRF(1) receptors mediate the stimulation of colonic transit induced by central CRF, urocortins (1 and 2) and restraint stress, while CRF(2) receptors mediate the inhibitory actions of these peptides on gastric transit.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Dose-related effects of i.c.v. r/hCRF and CRF-related peptides on fecal pellet output in conscious mice
Under short-duration enflurane anaesthesia, mice fed ad libitum were injected i.c.v. with vehicle (saline solution, 5μl), r/hCRF (0.01, 0.1, 0.5 or 1.0μg), oCRF (0.01, 0.1 or 0.5μg), rat urocortin 1 (rUcn 1: 0.01, 0.1 or 0.5μg), mouse urocortin 2 (mUcn 2: 0.01, 0.1 or 0.5μg), mouse urocortin 3 (mUcn 3: 0.1, 0.5 or 1.0μg) or oCRF9–33OH (0.5μg). Each point represents the mean ±s.e. of cumulative number of pellets for 1h after i.c.v. injection (n= 5–12mice/group). *P<0.05 versus vehicle-treated group (ANOVA); #P<0.05 versus r/hCRF at the same dose.
Figure 2
Figure 2. Time course of i.c.v. r/hCRF- (A), rUcn 1- (B) and mUcn 2- (C) induced fecal pellet output in mice
Under enflurane anaesthesia, mice fed ad libitum were injected i.c.v. with vehicle (saline solution, 5μl), r/hCRF (0.01, 0.1, 0.5 or 1.0μg), rat urocortin 1 (rUcn 1: 0.01, 0.1 or 0.5μg) or mouse urocortin 2 (mUcn 2: 0.01, 0.1 or 0.5μg). Each point represents the mean ±s.e. of number of pallets monitored at each 15min interval for 60min (n= 5–12mice/group). *P<0.05 versus vehicle-treated group (ANOVA).
Figure 3
Figure 3. Effects of i.c.v. CRF receptor antagonists on i.c.v. r/hCRF- (A), rUcn 1- (B) and mUcn 2- (C) induced stimulation of fecal pellet output in conscious mice
Under enflurane anaesthesia, mice fed ad libitum were injected i.c.v. with vehicle (distilled water, 2.5μl), the non-selective CRF1/CRF2 antagonist astressin (10μg), the selective CRF1 antagonist NBI-35965 (50 or 100μg), or the selective CRF2 antagonist astressin2-B (10μg). Immediately thereafter vehicle (saline solution, 2.5μl), r/hCRF (0.5μg), rat urocortin 1 (rUcn 1, 0.5μg) or mouse urocortin 2 (mUcn 2, 0.5μg) was administered i.c.v. Each point represents the mean ±s.e. of cumulative number of pellets for 1h after i.c.v. injection (n= 4–6mice/group). *P<0.05 versus vehicle+vehicle- or antagonist+vehicle-treated groups; #P<0.05 versus vehicle+respective peptide-treated groups (ANOVA).
Figure 4
Figure 4. Effects of i.c.v. injection of r/hCRF and CRF-related peptides on gastric emptying of a solid nutrient meal (A, C) and distal colonic transit time (B, D) monitored simultaneously in conscious mice
Groups of fasted mice were given chow ad libitum for 1 h, then under short-duration enflurane anaesthesia were injected i.c.v. with either saline (5μl), r/hCRF or mouse urocortin 2 (mUcn 2, 0.01–0.5μg), oCRF, rat urocortin 1 (rUcn 1), mouse urocortin 3 (mUcn 3) or oCRF9-33 0H (0.5μg) and a glass bead was inserted into the distal colon 2 cm proximal from the anus. Gastric emptying of the ingested meal 2h after peptide administration (A, C) and the time for bead expulsion (B, D) were monitored in the same animal. *P<0.05 versus vehicle-treated group (ANOVA); #P<0.05 versus r/hCRF at the same dose.
Figure 5
Figure 5. Effects of i.c.v. CRF receptor antagonists on i.c.v. r/hCRF-, rUcn 1- and mUcn 2-induced inhibition of gastric emptying and stimulation of distal colonic transit in conscious mice
Groups of fasted mice were given chow ad libitum for 1 h, then under short-duration enflurane anaesthesia were injected i.c.v. with distilled water (2.5μl), the selective CRF1 antagonist NBI-35965 (50μg) or the selective CRF2 antagonist astressin2-B (10μg). Immediately thereafter, saline (2.5μl), r/hCRF, rat urocortin 1 (rUcn 1) or mouse urocortin 2 (mUcn 2, 0.5μg) was injected i.c.v. and a glass bead was inserted into the distal colon 2 cm proximal from the anus. Gastric emptying of the ingested meal 2h after peptide administration (left axis) and the time for bead expulsion (right axis) were monitored in the same animal. The dashed lines represent the mean gastric emptying rate (41.2±5.0%) and bead latency time (11.8±1.2min) in animals treated with vehicles or antagonists+vehicle. *P<0.05 versus vehicle-treated group (ANOVA).
Figure 6
Figure 6. Effects of i.c.v. CRF receptor antagonists on restraint stress-induced defecation in mice
Groups of mice fed ad libitum were injected i.c.v., under short-duration enflurane anaesthesia, with distilled water (5μl), the non-selective CRF1/CRF2 antagonist astressin (10μg), the selective CRF1 antagonist NBI-35965 (50 or 100μg) or the selective CRF2 antagonist astressin2-B (10μg). Thereafter mice were subjected to a 1h session of stress (restraint in a cylinder) or left undisturbed in their home cages (non-stress). Pellet output was monitored at 15min intervals for the following 60min. A, cumulative pellet output for the 1h experimental time. B, time course changes in fecal pellet output at 15min intervals. *P<0.05 versus non-stress; #P<0.05 versus vehicle+stress group (ANOVA).

Similar articles

Cited by

References

    1. Bakshi VP, Smith-Roe S, Newman SM, Grigoriadis DE, Kalin NH. Reduction of stress-induced behavior by antagonism of corticotropin-releasing hormone 2 (CRH2) receptors in lateral septum or CRH1 receptors in amygdala. J Neurosci. 2002;22:2926–2935. - PMC - PubMed
    1. Bale TL, Picetti R, Contarino A, Koob GF, Vale WW, Lee KF. Mice deficient for both corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2 have an impaired stress response and display sexually dichotomous anxiety-like behavior. J Neurosci. 2002;22:193–199. - PMC - PubMed
    1. Behan DP, Heinrichs SC, Troncoso JC, Liu XJ, Kawas CH, Ling N, De Souza EB. Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer's disease. Nature. 1995;378:284–287. - PubMed
    1. Chen CY, Million M, Adelson DW, Martinez V, Rivier J, Taché Y. Intracisternal urocortin inhibits vagally stimulated gastric motility in rats: role of CRF(2) Br J Pharmacol. 2002;136:237–247. - PMC - PubMed
    1. Dautzenberg FM, Hauger RL. The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci. 2002;23:71–77. - PubMed

Publication types

MeSH terms

LinkOut - more resources